Drug Patents owned by Novartis

1. Drug name - AFINITOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment Nov, 2025

(3 years from now)

US8410131

(Pediatric)

NOVARTIS Cancer treatment May, 2026

(3 years from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment Jul, 2028

(5 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

2. Drug name - AMTURNIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8183295 NOVARTIS Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic May, 2023

(7 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE;EQ 5MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 5MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 5MG BASE;25MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 10MG BASE;12.5MG TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 10MG BASE;25MG TABLET;ORAL Discontinued

3. Drug name - ARCAPTA NEOHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

CN1156451C NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

CN1353692A NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

IN222346B NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

IN200101673P4 NOVARTIS Beta 2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915A1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915B1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP1183240A1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

EP1183240B1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 75MCG BASE POWDER;INHALATION Discontinued

4. Drug name - CIPRODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650 NOVARTIS Method of treating middle ear infections Jun, 2025

(2 years from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS;OTIC

More Information on Dosage
Strength Dosage Availability
0.3%;0.1% SUSPENSION/DROPS;OTIC Prescription

5. Drug name - EXFORGE HCT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same May, 2023

(7 months from now)

US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents May, 2023

(7 months from now)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same Nov, 2023

(1 year, 1 month from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE;12.5MG;160MG TABLET;ORAL Prescription
EQ 5MG BASE;25MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;12.5MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;25MG;160MG TABLET;ORAL Prescription
EQ 10MG BASE;25MG;320MG TABLET;ORAL Prescription

6. Drug name - GILENYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Mar, 2026

(3 years from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Sep, 2026

(3 years from now)

US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Jun, 2027

(4 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Dec, 2027

(5 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator Dec, 2027

(5 years from now)

US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Sep, 2032

(9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription

7. Drug name - HYCAMTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods Dec, 2024

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 1MG BASE CAPSULE;ORAL Prescription

8. Drug name - ILEVRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers Jun, 2024

(1 year, 8 months from now)

US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions Dec, 2030

(8 years from now)

US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions Mar, 2032

(9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.3% SUSPENSION/DROPS;OPHTHALMIC Prescription

9. Drug name - IZBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561 NOVARTIS Pharmaceutical compositions having desirable bioavailability Mar, 2029

(6 years from now)

US8754123 NOVARTIS Pharmaceutical compositions having desirable bioavailability May, 2029

(6 years from now)

US8178582 NOVARTIS Pharmaceutical compositions having desirable bioavailability Oct, 2029

(7 years from now)

US8722735 NOVARTIS Pharmaceutical compositions having desirable bioavailability Oct, 2029

(7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.003% SOLUTION/DROPS;OPHTHALMIC Discontinued

10. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(9 years from now)

CN103201275A NOVARTIS Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof
Dec, 2015

(6 years ago)

CN103788100A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Jun, 2017

(5 years ago)

CN101594871A NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN101594871B NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN102186856B NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN102186856A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN105384741B NOVARTIS A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105384741A NOVARTIS Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

IN283133B NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

IN200809406P1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145B1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145A2 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2331547A1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547B1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2638030A1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

EP2638030B1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses Dec, 2029

(7 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov, 2031

(9 years from now)

US10799506 NOVARTIS Ribociclib tablet Apr, 2036

(13 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; in combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

11. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(9 years from now)

CN103201275A NOVARTIS Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof
Dec, 2015

(6 years ago)

CN103788100A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Jun, 2017

(5 years ago)

CN101594871A NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN101594871B NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN102186856B NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN102186856A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN105384741B NOVARTIS A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105384741A NOVARTIS Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

IN283133B NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

IN200809406P1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145B1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145A2 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2331547A1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547B1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2638030A1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

EP2638030B1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses Dec, 2029

(7 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov, 2031

(9 years from now)

US10799506 NOVARTIS Ribociclib tablet Apr, 2036

(13 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

12. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(6 months ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(5 months ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(4 months from now)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(1 year, 29 days from now)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(1 year, 2 months from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(4 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

CN1312856A NOVARTIS Enzymatic Nucleic Acid Treatment Of Diseases Or Conditions Associated With Hepatitis C Virus Infection
Nov, 2004

(17 years ago)

CN1630724A NOVARTIS Method For Inhibiting Expression Of Target Gene
Jan, 2007

(15 years ago)

CN1608131A NOVARTIS Medicine For Treating Pancreatic Cancer
Jan, 2009

(13 years ago)

CN1608133A NOVARTIS Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers
Sep, 2009

(13 years ago)

CN1604783A NOVARTIS The Medicine For Treating Fibrosis Disease By Rna Interference
Dec, 2009

(12 years ago)

CN1650010A NOVARTIS Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease
Jan, 2010

(12 years ago)

CN101605892A NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus
Aug, 2012

(10 years ago)

CN102124107A NOVARTIS Rna Interference Mediated Inhibition Of Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Gene Expression Using Short Interfering Nucleic Acid (Sina)
May, 2013

(9 years ago)

CN101426912A NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Jun, 2013

(9 years ago)

CN102006890A NOVARTIS Targeting Lipid
Oct, 2015

(6 years ago)

CN101484588B NOVARTIS Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene
May, 2019

(3 years ago)

CN101484588A NOVARTIS Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene
May, 2019

(3 years ago)

CN1835897A NOVARTIS Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank
Aug, 2024

(1 year, 10 months from now)

CN1835897B NOVARTIS Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank
Aug, 2024

(1 year, 10 months from now)

CN104854242A NOVARTIS Pcsk9 Irna Composition And Using Method Thereof
Dec, 2033

(11 years from now)

CN104854242B NOVARTIS Pcsk9 Irna Composition And Using Method Thereof
Dec, 2033

(11 years from now)

IN200300537P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN213846B NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300572P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN203882B NOVARTIS Method For Inhibiting The Expression Of A Targe Gene
Jan, 2022

(8 months ago)

IN200806166P4 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

IN269138B NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

IN368763B NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

IN201503007P4 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP748382B1 NOVARTIS Non-Nucleotide Containing Enzymatic Nucleic Acid
Aug, 2014

(8 years ago)

EP748382A1 NOVARTIS Non-Nucleotide Containing Enzymatic Nucleic Acid
Aug, 2014

(8 years ago)

EP725788B1 NOVARTIS 2'-Amido And 2'-Peptido Modified Oligonucleotides
Oct, 2014

(7 years ago)

EP725788A1 NOVARTIS 2'-Amido And 2'-Peptido Modified Oligonucleotides
Oct, 2014

(7 years ago)

EP728205B1 NOVARTIS Reagent For Treatment Of Arthritic Conditions
Nov, 2014

(7 years ago)

EP728205A1 NOVARTIS Reagent For Treatment Of Arthritic Conditions
Nov, 2014

(7 years ago)

EP1408111A3 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP1408111B1 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP1408111A2 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP928290B9 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290A4 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290A1 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290B1 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP1214945A2 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945A3 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP2363479B1 NOVARTIS Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP1214945B2 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719B1 NOVARTIS Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945B1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719A1 NOVARTIS Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP2363479A1 NOVARTIS Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP1144623A1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B9 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285B1 NOVARTIS Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285A1 NOVARTIS Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1349927B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1349927A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1352061A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B9 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP2213736B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2415486B1 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP2415486A2 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP2415486A3 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP1423404A2 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404A4 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404B1 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2278004A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2902406A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128B1 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2287305B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A4 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A2 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2902406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP3354656A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A4 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157B1 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP3354656B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A2 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2278004B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1562971A2 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1560840A4 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1562971B1 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP2957568B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1560840B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1562971A4 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1560840A2 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP2957568A1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 29 days from now)

EP1605978A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A4 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A3 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1615611A2 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611A4 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611B1 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1620544A4 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544A2 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544B1 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1622572A2 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1622572B1 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1622572A4 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1627061B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
May, 2024

(1 year, 7 months from now)

EP1627061A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
May, 2024

(1 year, 7 months from now)

EP1765074A4 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 7 months from now)

EP1765074A2 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 7 months from now)

EP1765074B1 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 7 months from now)

EP1667944B1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1667944A1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1664299A1 NOVARTIS Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Sep, 2024

(1 year, 11 months from now)

EP1664299B1 NOVARTIS Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Sep, 2024

(1 year, 11 months from now)

EP1677822B1 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A2 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A4 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1713915A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
Feb, 2025

(2 years from now)

EP1713915B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
Feb, 2025

(2 years from now)

EP1799270B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270A2 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270A4 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1931781B1 NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Aug, 2026

(3 years from now)

EP1931781A2 NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Aug, 2026

(3 years from now)

EP2584047B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584047A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2231195B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231194B1 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077A1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231195A2 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2929031B9 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP2929031A1 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP2929031B1 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation Nov, 2023

(1 year, 29 days from now)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene Dec, 2027

(5 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder Aug, 2036

(13 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

13. Drug name - MAYZENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
May, 2024

(1 year, 7 months from now)

CN102174042B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN102174042A NOVARTIS Immunosuppressant Compound And Composition
Jul, 2015

(7 years ago)

CN1791592A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1787817A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1791592B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1787817B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1816544B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1816544A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1791395A NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

CN1791395B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN234287B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN200503060P4 NOVARTIS Immunosuppresant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist Nov, 2030

(8 years from now)

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription

14. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(8 years from now)

CN101912400A NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN101006086A NOVARTIS 5-Amido-2, 4, 7-Trioxy-3, 4, 7, 8-Tetrahydropyranyl Ether-2H-Naphthyridine [2,3-D] Pyrimidine Derivatives And Correlative Compound Used For Curing Cancer
Jun, 2025

(2 years from now)

CN101912400B NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN101006086B NOVARTIS For The 5 - -2, 4, 7 - -3, 4, 7, 8-Tetrahydro - -2H - Pyrido [2, 3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN102655753A NOVARTIS Combination
Oct, 2030

(8 years from now)

CN102655753B NOVARTIS Combined Medicine
Oct, 2030

(8 years from now)

IN200700102P4 NOVARTIS Pyrimidine Compound And Medical Use Thereof
Jun, 2025

(2 years from now)

IN237689B NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyridio[2,3-D]Pyrimidine Derivatives And A Pharmaceutical Composition Comprising The Same
Jun, 2025

(2 years from now)

EP2298768B9 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2298768B1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2298768A1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP1761528A1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP1761528B1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2488033A1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033B1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033A4 NOVARTIS Combination
Oct, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof Jun, 2025

(2 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct, 2030

(8 years from now)

US8580304 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9399021 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9271941 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9155706 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

15. Drug name - MOXEZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug May, 2029

(6 years from now)

US9114168 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug May, 2029

(6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

16. Drug name - NEVANAC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324281 NOVARTIS Topical nepafenac formulations Dec, 2025

(3 years from now)

US8071648 NOVARTIS Topical nepafenac formulations Dec, 2025

(3 years from now)

US7834059 NOVARTIS Topical nepafenac formulations Jan, 2027

(4 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: Method of treating ocular inflammation

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SUSPENSION/DROPS;OPHTHALMIC Prescription

17. Drug name - PATANASE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977376 NOVARTIS Olopatadine formulations for topical nasal administration Feb, 2023

(3 months from now)

US8399508

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration Mar, 2023

(5 months from now)

US7977376

(Pediatric)

NOVARTIS Olopatadine formulations for topical nasal administration Aug, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
0.665MG/SPRAY SPRAY, METERED;NASAL Prescription

18. Drug name - PIQRAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

19. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(a month from now)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(2 years from now)

CN101343250A NOVARTIS Thrombopoietin Mimics
May, 2020

(2 years ago)

CN101343251B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343250B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343251A NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN100423721C NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN1444477A NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN100542530C NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine)
May, 2023

(7 months from now)

CN1652842A NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine)
May, 2023

(7 months from now)

IN200201666P3 NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN213176B NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN200403400P1 NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

IN233161B NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1889838B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1889838A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B8 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1534390B1 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A2 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A4 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1294378A2 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378B1 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378A4 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics May, 2023

(7 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May, 2023

(7 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov, 2023

(1 year, 1 month from now)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jan, 2026

(3 years from now)

US8828430 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8071129 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8062665 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8052994 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8052993 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8062665

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8071129

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8828430

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8052993

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

US8052994

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb, 2028

(5 years from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of idiopathic thrombocytopenic purpura (itp); patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID TABLET;ORAL Prescription
EQ 25MG ACID TABLET;ORAL Prescription
EQ 50MG ACID TABLET;ORAL Prescription
EQ 75MG ACID TABLET;ORAL Prescription
EQ 100MG ACID TABLET;ORAL Discontinued

20. Drug name - PROMACTA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(a month from now)

US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(2 years from now)

CN101343250A NOVARTIS Thrombopoietin Mimics
May, 2020

(2 years ago)

CN101343251B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343250B NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN101343251A NOVARTIS Thrombopoietin Mimetics
May, 2020

(2 years ago)

CN100423721C NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN1444477A NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

CN100542530C NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethylphenyl) 1, 5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4] Hydrazino] 2 ' - Hydroxy - [1 1 ' - Biphenyl] - 3-Di - (Monoethanolamine)
May, 2023

(7 months from now)

CN1652842A NOVARTIS 3 '-[(2Z)-[3 - (1, 4-Dimethyl-Phenyl)--1, 5-Dihydro - -3 - Methyl - -5 - Oxo - -4H - Pyrazol - -4 - Pyrazol-4-Ylidene] Hydrazino] -2 ' - Hydroxy - [1 1 ' - Biphenyl]--3 - Di - (Monoethanolamine)
May, 2023

(7 months from now)

IN200201666P3 NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN213176B NOVARTIS A Compound And A Pharmaceutical Composition For Use In Enhancing Platelet Production
May, 2021

(1 year, 4 months ago)

IN200403400P1 NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,2'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

IN233161B NOVARTIS 3'-[(2Z)-[1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene]Hydrazino]-2'-Hydroxy-[1,1'-Biphenyl]-3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1889838B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1889838A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981A1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B1 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1864981B8 NOVARTIS Thrombopoietin Mimetics
May, 2021

(1 year, 4 months ago)

EP1534390B1 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A2 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1534390A4 NOVARTIS 3'- (2Z)- 1-(3,4-Dimethylphenyl)-1,5-Dihydro-3-Methyl-5-Oxo-4H-Pyrazol-4-Ylidene Hydrazino -2'-Hydroxy- 1,1'-Biphenyl -3-Carboxylic Acid Bis-(Monoethanolamine)
May, 2023

(7 months from now)

EP1294378A2 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378B1 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

EP1294378A4 NOVARTIS Thrombopoietin Mimetics
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160870

(Pediatric)

NOVARTIS Thrombopoietin mimetics May, 2023

(7 months from now)

US7795293 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May, 2023

(7 months from now)

US7795293

(Pediatric)

NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov, 2023

(1 year, 1 month from now)

US7547719

(Pediatric)

NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jan, 2026

(3 years from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID/PACKET FOR SUSPENSION;ORAL Prescription
EQ 25MG ACID/PACKET FOR SUSPENSION;ORAL Prescription

21. Drug name - RECLAST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates Oct, 2023

(1 year, 21 days from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates Aug, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

22. Drug name - RYDAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity Oct, 2022

(23 days from now)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity Oct, 2024

(2 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives Dec, 2030

(8 years from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription

23. Drug name - SCEMBLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(10 years from now)

CN104302638B NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302638A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634B NOVARTIS For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives
May, 2033

(10 years from now)

EP2861579B9 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861576B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861576A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

24. Drug name - SEEBRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation Oct, 2028

(6 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
15.6MCG/INH POWDER;INHALATION Discontinued

25. Drug name - TAFINLAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(7 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(7 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(8 years from now)

CN102083312A NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

CN102083312B NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

CN102655753A NOVARTIS Combination
Oct, 2030

(8 years from now)

CN102655753B NOVARTIS Combined Medicine
Oct, 2030

(8 years from now)

IN275655B NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

IN201004199P2 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636A4 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636B1 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2282636A2 NOVARTIS Benzene Sulfonamide Thiazole And Oxazole Compounds
May, 2029

(6 years from now)

EP2488033A1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033B1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033A4 NOVARTIS Combination
Oct, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof Jun, 2025

(2 years from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds May, 2029

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct, 2030

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test; Tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test.; Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 75MG BASE CAPSULE;ORAL Prescription

26. Drug name - TASIGNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(8 months from now)

US8415363 NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Jul, 2026

(3 years from now)

US8163904 NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Aug, 2028

(5 years from now)

US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

CN102358736A NOVARTIS 4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide
Mar, 2015

(7 years ago)

CN102267981A NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide
Jun, 2015

(7 years ago)

CN103804356A NOVARTIS 4-Methyl-N-[3-(4-Methyl-Imidazol--1-Base)--5-Trifluoromethyl-Phenyl]--3-(4-Pyridin--3-Base-Pyrimidin--2-Ylamino)-Benzamide Of Crystalline Form
Mar, 2016

(6 years ago)

CN1675195A NOVARTIS Tyrosine Kinase Inhibitors
Jul, 2023

(8 months from now)

CN1324022C NOVARTIS Tyrosine Kinase Inhibitors
Jul, 2023

(8 months from now)

CN101228151B NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidine-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

CN101228150B NOVARTIS 4-Methyl-N - [4 - (3-Methyl-Imidazole - -1 - Yl)--5 - Trifluoromethyl-Phenyl] -3-(4-Pyridine - -3 - Yl-Pyrimidine - -2 - Ylamino) - Form Benzamide
Jul, 2026

(3 years from now)

CN101228150A NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

CN101228151A NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Base-Pyrimidin-2-Yl-Amino)-Benzamide
Jul, 2026

(3 years from now)

CN102612368A NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

CN102612368B NOVARTIS Method Of Treating Proliferation Disorders And Other Pathological Conditions Mediated By Bar-Abl, C-Kit, Ddr1 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

IN237430B NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

IN200403003P4 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP1532138B1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2357182A1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2357182B1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP1532138A1 NOVARTIS Inhibitors Of Tyrosine Kinases
Jul, 2023

(8 months from now)

EP2535337B1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form
Jul, 2026

(3 years from now)

EP2535337A1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate And Its Amorphous Form
Jul, 2026

(3 years from now)

EP1912973B1 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167A2 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2186808A1 NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1910336B1 NOVARTIS Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167B2 NOVARTIS Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167B1 NOVARTIS Crystalline Form Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1910336A1 NOVARTIS Monohydrochloride Monohydrate Salt Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2186808B1 NOVARTIS Salts Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP1912973A2 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2284167A3 NOVARTIS Crystalline Forms Of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-Yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-Yl-Pyrimidin-2-Ylamino)-Benzamide
Jul, 2026

(3 years from now)

EP2501384B1 NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

EP2501384A1 NOVARTIS Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169791

(Pediatric)

NOVARTIS Inhibitors of tyrosine kinases Jan, 2024

(1 year, 2 months from now)

US8501760 NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt Jul, 2026

(3 years from now)

US8389537 NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jul, 2026

(3 years from now)

US8415363

(Pediatric)

NOVARTIS Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jan, 2027

(4 years from now)

US8389537

(Pediatric)

NOVARTIS Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Jan, 2027

(4 years from now)

US8501760

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib or its salt Jan, 2027

(4 years from now)

US8293756 NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate Sep, 2027

(4 years from now)

US8293756

(Pediatric)

NOVARTIS Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate Mar, 2028

(5 years from now)

US8163904

(Pediatric)

NOVARTIS Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide Feb, 2029

(6 years from now)

US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity Oct, 2032

(10 years from now)

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription
EQ 200MG BASE CAPSULE;ORAL Prescription

27. Drug name - TEKAMLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949 NOVARTIS Galenical formulations of organic compounds Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE;EQ 5MG BASE TABLET;ORAL Discontinued
EQ 150MG BASE;EQ 10MG BASE TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 5MG BASE TABLET;ORAL Discontinued
EQ 300MG BASE;EQ 10MG BASE TABLET;ORAL Discontinued

28. Drug name - TRAVATAN Z

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8388941 NOVARTIS Self preserved aqueous pharmaceutical compositions Sep, 2027

(4 years from now)

US8323630 NOVARTIS Self-preserved aqueous pharmaceutical compositions Sep, 2027

(4 years from now)

US8268299 NOVARTIS Self preserved aqueous pharmaceutical compositions Oct, 2029

(7 years from now)

Drugs and Companies using TRAVOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.004% SOLUTION/DROPS;OPHTHALMIC Prescription

29. Drug name - TRIESENCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection Mar, 2029

(6 years from now)

US8128960 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection Dec, 2029

(7 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: Visualization during vitrectomy procedures; treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

More Information on Dosage
Strength Dosage Availability
40MG/ML (40MG/ML) INJECTABLE;INTRAVITREAL Prescription

30. Drug name - TYKERB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8821927 NOVARTIS Pharmaceutical composition
Sep, 2029

(6 years from now)

CN101203211A NOVARTIS Medicine Composition
Apr, 2026

(3 years from now)

CN101203211B NOVARTIS Drug Composition
Apr, 2026

(3 years from now)

EP1871347A1 NOVARTIS Pharmaceutical Composition
Apr, 2026

(3 years from now)

EP1871347A4 NOVARTIS Pharmaceutical Composition
Apr, 2026

(3 years from now)

EP1871347B1 NOVARTIS Pharmaceutical Composition
Apr, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE TABLET;ORAL Prescription

31. Drug name - TYZEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(11 months from now)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(11 months from now)

CN100376593C NOVARTIS L-2 ' - Deoxythymidine Of Crystallized And Amorphous
Aug, 2023

(9 months from now)

CN1714098A NOVARTIS L-2 ' - Deoxythymidine Of Crystallized And Amorphous
Aug, 2023

(9 months from now)

EP1534727B1 NOVARTIS Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine
Aug, 2023

(9 months from now)

EP1534727A4 NOVARTIS Crystalline And Amorphous Forms Of Beta-L-2 -Deoxythymidine
Aug, 2023

(9 months from now)

EP1534727A2 NOVARTIS Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine
Aug, 2023

(9 months from now)

More Information on Dosage
Strength Dosage Availability
600MG TABLET;ORAL Discontinued

32. Drug name - UTIBRON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

CN1156451C NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

CN1353692A NOVARTIS Adrenoreceptor Agonist
Jun, 2020

(2 years ago)

IN222346B NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

IN200101673P4 NOVARTIS Beta 2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915A1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP2332915B1 NOVARTIS Beta2-Adrenoceptor Agonists
Jun, 2020

(2 years ago)

EP1183240A1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

EP1183240B1 NOVARTIS Beta2-Adrenoceptor Agonists
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device Oct, 2028

(6 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation Oct, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
15.6MCG/INH;27.5MCG/INH POWDER;INHALATION Discontinued

33. Drug name - VALTURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168616 NOVARTIS Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension Jul, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE;160MG TABLET;ORAL Discontinued
EQ 300MG BASE;320MG TABLET;ORAL Discontinued

34. Drug name - VOTRIENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(1 year, 13 days from now)

CN1549813A NOVARTIS As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis
Dec, 2021

(9 months ago)

CN1307173C NOVARTIS As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis
Dec, 2021

(9 months ago)

IN200300818P2 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

IN210284B NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP2311825A1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP2311825B1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP1343782B1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Jun, 2025

(2 years from now)

EP1343782A1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Jun, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Discontinued

35. Drug name - XIIDRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7928122 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(2 years from now)

US7745460 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(2 years from now)

US7314938 NOVARTIS Modulators of cellular adhesion
Mar, 2025

(2 years from now)

US8084047 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US9890141 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(8 years from now)

CN105820160A NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN1902195B NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN105820160B NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN1902195A NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

CN101175488B NOVARTIS Compositions And Methods For Treating Eye Disease
May, 2026

(3 years from now)

CN101175488A NOVARTIS Composition And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

IN279168B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN200601233P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN201003759P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN250181B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN201100459P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN348854B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN284595B NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

IN200708114P1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1682537B1 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

EP1682537A1 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

EP1881823A4 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1881823A1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP2444079B1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1881823B1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP2444079A1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216174 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US7790743 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US10124000 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US8592450 NOVARTIS Compositions and methods for treatment of eye disorders May, 2026

(3 years from now)

US8367701 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Apr, 2029

(6 years from now)

US9447077 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Apr, 2029

(6 years from now)

US8168655 NOVARTIS Compositions and methods for treatment of eye disorders May, 2029

(6 years from now)

US9353088 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Oct, 2030

(8 years from now)

US8927574 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Nov, 2030

(8 years from now)

US9085553 NOVARTIS LFA-1 inhibitor and methods of preparation and polymorph thereof Jul, 2033

(10 years from now)

US11058677 NOVARTIS LFA-1 inhibitor formulations Dec, 2033

(11 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
5% SOLUTION/DROPS;OPHTHALMIC Prescription

36. Drug name - ZOMETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases May, 2025

(2 years from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases Nov, 2025

(3 years from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Multiple myeloma; bone metastases; hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE;INTRAVENOUS Discontinued
EQ 4MG BASE/5ML INJECTABLE;INTRAVENOUS Prescription
EQ 4MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

37. Drug name - ZYKADIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(3 years from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(5 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(5 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(7 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(9 years from now)

CN101514191A NOVARTIS Method Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jun, 2011

(11 years ago)

CN102317268A NOVARTIS 2-Biphenylamion-4-Aminopyrimidine Derivatives As Kinase Inhibitors
Jul, 2014

(8 years ago)

CN101616895A NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Sep, 2014

(8 years ago)

CN103282359A NOVARTIS 5-Chloro--N2-(2-Isopropoxy--5-Methyl--4-Piperidin--4-Yl-Phenyl)--N4-[2-(Propane--2-Sulfonyl)-Phenyl]--2, 4-Diamine In Crystalline Form.
Jun, 2017

(5 years ago)

CN104262324A NOVARTIS 5 - -N2-(2-Isopropoxy - -5 - Methyl - -4 - Piperidine - -4 - Yl-Phenyl)--N4-[2 - (Propane - -2 - Sulphonyl) - Phenyl]--2, 4-Diamine In Crystalline Form
Jul, 2017

(5 years ago)

CN107056751A NOVARTIS Crystalline Form Of Alk Inhibitor
Mar, 2021

(1 year, 6 months ago)

CN1625400B NOVARTIS 2, 4-Pyridine Diamine Compound And Application Thereof
Jan, 2023

(3 months from now)

CN1625400A NOVARTIS 2, 4-Pyrimidine Diamine Compound And Use Thereof
Jan, 2023

(3 months from now)

CN102174024B NOVARTIS 2, 4-Pyridine Diamine Compound And Application Thereof
Jan, 2023

(3 months from now)

CN102174024A NOVARTIS 2,4-Pyrimidinediamine Compounds And Application Thereof
Jan, 2023

(3 months from now)

CN103169708A NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

CN103169708B NOVARTIS 2, 4-Pyrimidine Diamine Compound For Treating Or Preventing Autoimmune Disease In A Subject
Jul, 2023

(9 months from now)

CN1788001B NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN101921236B NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN101921236A NOVARTIS 2,4-Di(Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN1788001A NOVARTIS Can Be Used For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders For 2, 4-Di (Phenylamino) Pyrimidine
Mar, 2024

(1 year, 5 months from now)

CN1832929B NOVARTIS 2, 4-Thonzylamine For Treating Neoplasia Disease, Inflammation And The Immune System Disorder
Mar, 2024

(1 year, 5 months from now)

CN1832929A NOVARTIS For Treating Neoplastic Disease, Inflammation, And Diseases Of The Immune System Of 2, 4-Pyrimidine Diamine
Mar, 2024

(1 year, 5 months from now)

IN200401139P2 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

IN239514B NOVARTIS 2,4 - Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

IN200502241P4 NOVARTIS 2,4-Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

IN232653B NOVARTIS 2,4-Di(Phenylamino)Pyrimidines For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

IN200600553P4 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

IN240560B NOVARTIS 2,4-Pyrimidinediamines And A Pharmaceutical Composition Comprising The Same
Aug, 2024

(1 year, 10 months from now)

IN200903951P1 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

IN276026B NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2091918B1 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Jul, 2020

(2 years ago)

EP2091918A2 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Jul, 2020

(2 years ago)

EP2651918A1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Jun, 2022

(4 months ago)

EP2651918B1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Jun, 2022

(4 months ago)

EP2281563B1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915A2 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP2281563A1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915A4 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915B1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1534286B1 NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

EP2316459B1 NOVARTIS 2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases
Jul, 2023

(9 months from now)

EP2316459A1 NOVARTIS 2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases
Jul, 2023

(9 months from now)

EP1534286A1 NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

EP1606265A1 NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP1606265B1 NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2275413B1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2275413A1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2287156A1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP1660458A1 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP1660458B1 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP2287156B1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP2311807B1 NOVARTIS Compounds And Composition As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2311807A1 NOVARTIS Compounds And Composition As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP3121171B1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Dec, 2031

(9 years from now)

EP3453708B1 NOVARTIS Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

EP3121171A1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Dec, 2031

(9 years from now)

EP3453708A1 NOVARTIS Process For The Preparation Of 5-Chloro-N-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N-2-(Isopropylsulfonyl)Phenyl)-2,4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

EP3453708B8 NOVARTIS Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors Nov, 2027

(5 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors Feb, 2032

(9 years from now)

Drugs and Companies using CERITINIB ingredient

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.